Rheumatology & Autoimmune

Arthritis, lupus, vasculitis, biologics, and immune‑modulating therapies.

  • 3 Tracked terms
  • Last 30 days Feed window

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Rheumatology & Autoimmune


audacy.com > 947theblocknyc > news > muni-long-richest

Muni Long gets real about her journey with lupus and taking time with new music

13+ hour, 45+ min ago   (107+ words) Ask your smart speaker to play Ninety Four Seven The Block on Audacy The “Richest” singer sits down with Danie B Muni Long is in the building in Atlanta, sitting down with Danie B to talk about her newest single,…...


biospace.com > press-releases > vagus-nerve-stimulation-trial-is-available-to-patients-with-lupus

Vagus Nerve Stimulation Trial Is Available to Patients With Lupus

23+ hour, 22+ min ago   (234+ words) The bioelectronic medicine trial will study how non-invasive stimulation might treat pain and fatigue in patients with lupus This study, which is part of Northwell Health’s Center for Bioelectronic Medicine, builds upon Dr. Aranow’s previous clinical trial, which showed dramatic…...


themedicinemaker.com > issues > 2026 > articles > october > prula-cel-shows-early-promise-in-lupus

Prula-cel Shows Early Promise in Lupus

6+ day, 1+ hour ago   (282+ words) Adicet Bio has reported positive Phase I safety and efficacy data for prulacabtagene leucel (prula-cel), its investigational allogeneic gamma delta CAR T therapy, in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis. All patients discontinued immunosuppressant treatment,…...


globenewswire.com > news-release > 10/12/2026 > 3378786 > 0 > en > zenas-biopharma-announces-the-presentation-of-new-obexelimab-data-in-igg4-related-disease-at-the-6th-international-symposium-on-igg4-related-disease.html

Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease

1+ day, 18+ hour ago   (158+ words) October 12, 2026 07:00 ET | Source: Zenas BioPharma Follow Zenas BioPharma – Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab – – Additional analyses of secondary endpoints showed that significantly fewer patients experienced clinically meaningful cumulative glucocorticoid toxicity at week 52 – – These new findings…...


medicaldialogues.in > amp > orthopaedics > news > osteoarthritis-new-players-involved-in-joint-inflammation-178712

Osteoarthritis: New players involved in joint inflammation: Study

3+ week, 4+ day ago   (243+ words) “Our results show that these proteins are not merely markers of cellular stress. They actively contribute to the transformation of cells within the synovial membrane and to the maintenance of inflammation,” explains Zoé Gendebien, researcher at the Rheumatology Laboratory (University…...


bioengineer.org > when-lupus-strikes-the-brains-veins-rare-childhood-stroke-clue-emerges

When Lupus Strikes the Brain’s Veins: Rare Childhood Stroke Clue Emerges

2+ day, 3+ hour ago   (681+ words) A Chinese case series of eleven children with lupus identifies headache, transverse sinus involvement, elevated CRP and thrombocytopenia as the hallmark features of cerebral venous sinus thrombosis, with early combined treatment yielding favorable outcomes. Among the many complications that systemic…...


bioengineer.org > bacterial-biofilms-may-trigger-the-autoantibodies-behind-lupus-kidney-damage

Bacterial Biofilms May Trigger the Autoantibodies Behind Lupus Kidney Damage

2+ day, 7+ hour ago   (75+ words) New research in mice shows that curli amyloid fibers from Salmonella and E. coli biofilms can drive the production of anti-C1q and anti-dsDNA autoantibodies, linking infection and dysbiosis to lupus kidney disease. Subject of Research: The induction of anti-C1q and anti-dsDNA…...


medicaldaily.com > lupus-car-t-prula-cel-immunosuppressant-free-remission-trial-479286

Lupus Patients Stopped Every Immunosuppressant After One Off-the-Shelf CAR-T Dose in Small Trial, but Therapy Remains Experimental

1+ week, 6+ day ago   (758+ words) Every patient evaluated in a small early-stage lupus trial has stopped taking immunosuppressant drugs after a single infusion of an experimental donor-derived cell therapy, Adicet Bio reported on Sept. 28. More than half of the patients followed for a full year…...


hcplive.com > shorts > daxdilimab-improves-discoid-lupus-skin-activity-week-4

Daxdilimab Improves Discoid Lupus Skin Activity by Week 4

3+ day, 20+ hour ago   (103+ words) Victoria Werth, MD, of the University of Pennsylvania, discusses phase 2 findings showing that daxdilimab, an anti-ILT7 antibody that depletes plasmacytoid dendritic cells, improved skin activity in patients with discoid lupus at 2 doses vs placebo. She notes that improvement emerged by…...


physiciansweekly.com > post > oral-semaglutide-gains-early-acceptance-among-adults-with-obesity-2

Objective Inflammation Predicts Biologic Use in Early Spondyloarthritis

4+ day, 5+ hour ago   (166+ words) Instead, older age at diagnosis was linked to a lower likelihood of receiving advanced therapy (HR per standard deviation, 0.74; 95% CI, 0.55-1.00). Additional exploratory analyses demonstrated that patients aged 62 years and older were significantly less likely to initiate treatment with a bDMARD…...